Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

CNS 4Thoracic 2Other hematologic neoplasm 2Breast 2Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 902Lung Neoplasms 489Small Cell Lung Carcinoma 140Neoplasms 111Melanoma 107Neoplasm Metastasis 105Breast Neoplasms 99Colorectal Neoplasms 94Ovarian Neoplasms 76Carcinoma, Renal Cell 64Pancreatic Neoplasms 62Squamous Cell Carcinoma of Head and Neck 58Mesothelioma 53Stomach Neoplasms 51Head and Neck Neoplasms 47Adenocarcinoma of Lung 46Triple Negative Breast Neoplasms 45Esophageal Neoplasms 40Colonic Neoplasms 40Brain Neoplasms 40Sarcoma 38Mesothelioma, Malignant 38Prostatic Neoplasms 37Urinary Bladder Neoplasms 36Recurrence 30Carcinoma, Transitional Cell 28Uterine Cervical Neoplasms 25Endometrial Neoplasms 25Carcinoma, Hepatocellular 21Carcinoma, Squamous Cell 19

Interventions

Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Meningeal Neoplasms × Thoracic × Clear all
NCT05414123 2023-10-16

FORESEE

Biocept, Inc.

Terminated
40 enrolled
BreastCNSThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Neoplasms, Meningeal Carcinomatosis

NCT03711422 2022-06-14

Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

National Cancer Centre, Singapore

Phase 1 Terminated
2 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡